Are we all going to be replaced by robots? Not just yet ARTHUR trial: the robotic ultrasonographer vs. human While the concept is promising, and ICC with humans were low to moderate, the robot is overestimating grey scale scores in MCPs of both HC and RA pts #EULAR2025 https://t.co/mTtbknu0lO

• https://x.com/AurelieRheumo/status/1933156949190696983/photo/1
• https://x.com/AurelieRheumo/status/1933156949190696983/photo/1

Treatment strategies for steroid free management of #relapsingpolychondritis 56 patients from a single center #POS0149 #EULAR2025 @RheumNow https://t.co/d4I56opS02

• https://x.com/bella_mehta/status/1933157207526563956/photo/1

Multimodal data using clinical histological and serological predictors in renal function in #sle nephritis. Using the AMP SLE data. Low baseline eGFR and histological damage predicted worsening renal function but not NIH activity index #POS0173 #EULAR2025 @RheumNow @andreafa https://t.co/Eh8dZXHRVX

• https://x.com/bella_mehta/status/1933159461310599548/photo/1
• https://x.com/bella_mehta/status/1933159461310599548/photo/1
• https://x.com/bella_mehta/status/1933159461310599548/photo/1

#D2T #RA ~20% #Polyrefractory 3% Many reasons for d/c ing #Rx - D2T AEs Intolerance Chronic pain Etc My approach is different depending on reasons why drugs were d/c Ie ?obj inflammation vs pain or intolerance @RheumNow @eular_org #EULAR2025 #whatmakes D2T RA difficult https://t.co/AL6TMVJIk9

• https://x.com/Janetbirdope/status/1933161013836226975/photo/1

Would you use #CAR-T in #polyrefractory #RA #EULAR2025 @RheumNow @eular_org

POS0150: From 12 RA registries, JAKi starts fell by ~13% after FDA safety alerts. Tofa & bari took biggest hits; upa growth slowed but offset losses. Real-world prescribing adapts—but doesn’t abandon. @RheumNow #EULAR2025 https://t.co/QZ5haW2vhX

• https://x.com/JihaRheum/status/1933147276005822711/photo/1

?fishing for + results #EULAR2025 ⚠️opinion be aware that results do not live or die on P values Impt findings beyond primary endpoints may be Impt beyond P<0.05 Conversely Unexpected P values in a database ❎interpret w caution Consider as hypothesis only @RheumNow

Ultrasound for ILD detection in RA 🫁 Sens 88.6 Spe 92.8 NPV 91.4 PPV 90.7 While if abnormal or high suspicion, HRCT should be the reference, I see this as an interesting tool in clinics for quick screening POS0180 #EULAR2025 @RheumNow https://t.co/pUy0ki7Y6S

• https://x.com/AurelieRheumo/status/1933150468793938167/photo/1
• https://x.com/AurelieRheumo/status/1933150468793938167/photo/1

#HOT topic Lung 🫁 #ultrasound for #RA #ILD #LUS B lines vs HRCT Single site 🇫🇷 study V sensitive & specific 🤔needs standardization & comparison in other groups Abst#POS-180 #EULAR2025 @RheumNow @eular_org https://t.co/PwGE4rgk40

• https://x.com/Janetbirdope/status/1933150999352369385/photo/1

Software enhances treat to target outcomes for #RA GoTreatIT P0S0750 ##EULAR2025 @RheumNow https://t.co/GpihWr5KLA

• https://x.com/bella_mehta/status/1933154044681314416/photo/1
• https://x.com/bella_mehta/status/1933154044681314416/photo/1

Does having a synovitis in a specific joint predicts Rx damage in that same joint? Yes Can US synovitis predict Rx progression better than clinical synovitis at the joint level? Not really At 1 year, only US synovitis is, both B-mode and Doppler ass w/ Rx prog, in particular https://t.co/Wu6dDqIUYn

• https://x.com/AurelieRheumo/status/1933154089455468584/photo/1

Fascinating to see JAKi uptake in European JAK-pot centres - tofa was already on the decline pre-ORAL Surveillance - JAKi use (driven by upadacitinib) continues to grow, although maybe it’s slowed Hopefully rational JAKi has its place #EULAR2025 POS0150 @RheumNow https://t.co/XRyHJVw821

• https://x.com/drdavidliew/status/1933155241043910719/photo/1

Tenosynovitis of 5th compartment independently associated w/ D2T RA in a cohort of 90+ pts compared to established RA Erosions, Tenosynovitis and Synovitis non associated with D2T phenotype It’d be interesting to see if this could predict D2T evolution in early RA pts POS0185 https://t.co/faruOr3HhJ

• https://x.com/AurelieRheumo/status/1933155676785717538/photo/1

RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its faculty